Sarcopenia - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 61
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SDB104C729BEN
Leaflet:

Download PDF Leaflet

Sarcopenia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Sarcopenia - Pipeline Review, H2 2016’, provides an overview of the Sarcopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Sarcopenia
  • The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects
  • The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sarcopenia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sarcopenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Sarcopenia Overview
Therapeutics Development
Pipeline Products for Sarcopenia - Overview
Pipeline Products for Sarcopenia - Comparative Analysis
Sarcopenia - Therapeutics under Development by Companies
Sarcopenia - Therapeutics under Investigation by Universities/Institutes
Sarcopenia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Sarcopenia - Products under Development by Companies
Sarcopenia - Products under Investigation by Universities/Institutes
Sarcopenia - Companies Involved in Therapeutics Development
Atara Biotherapeutics, Inc.
Biophytis SAS
GlaxoSmithKline Plc
MYOS RENS Technology Inc.
Neurotune AG
Novartis AG
PsiOxus Therapeutics Limited
Regeneron Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sarcopenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-4210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
espindolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEP-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sarcopenia - Dormant Projects
Sarcopenia - Discontinued Products
Sarcopenia - Product Development Milestones
Featured News & Press Releases
Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th
Nov 17, 2015: Biophytis establishes Boston subsidiary to accelerate clinical development of Sarcob
Sep 21, 2015: BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference
Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Sarcopenia, H2 2016
Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Sarcopenia - Pipeline by Atara Biotherapeutics, Inc., H2 2016
Sarcopenia - Pipeline by Biophytis SAS, H2 2016
Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2016
Sarcopenia - Pipeline by MYOS RENS Technology Inc., H2 2016
Sarcopenia - Pipeline by Neurotune AG, H2 2016
Sarcopenia - Pipeline by Novartis AG, H2 2016
Sarcopenia - Pipeline by PsiOxus Therapeutics Limited, H2 2016
Sarcopenia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Sarcopenia - Dormant Projects, H2 2016
Sarcopenia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Sarcopenia, H2 2016
Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Atara Biotherapeutics, Inc.
Biophytis SAS
GlaxoSmithKline Plc
MYOS RENS Technology Inc.
Neurotune AG
Novartis AG
PsiOxus Therapeutics Limited
Regeneron Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Skip to top


Ask Your Question

Sarcopenia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: